Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-2lccl Total loading time: 0 Render date: 2024-04-27T03:25:14.699Z Has data issue: false hasContentIssue false

43 - Applications of Proteomics to Metastasis Diagnosis and Individualized Therapy

from PART II - CLINICAL RESEARCH

Published online by Cambridge University Press:  05 June 2012

By
Mariaelena Pierobon ,
Alessandra Luchini ,
Alessandra Silvestri ,
Virginia Espina ,
Emanuel F. Petricoin  and
Lance A. Liotta
Edited by
David Lyden ,
Danny R. Welch  and
Bethan Psaila
Mariaelena Pierobon
Affiliation:
George Mason University, United States
Alessandra Luchini
Affiliation:
George Mason University, United States
Alessandra Silvestri
Affiliation:
George Mason University, United States
Virginia Espina
Affiliation:
George Mason University, United States
Emanuel F. Petricoin
Affiliation:
George Mason University, United States
Lance A. Liotta
Affiliation:
George Mason University, United States
David Lyden
Affiliation:
Weill Cornell Medical College, New York
Danny R. Welch
Affiliation:
Weill Cornell Medical College, New York
Bethan Psaila
Affiliation:
Imperial College of Medicine, London
Get access

Summary

APPLICATION OF PROTEOMICS AND NANOTECHNOLOGY TO CANCER BIOMARKER DISCOVERY: CLINICAL NEED VERSUS PHYSIOLOGIC ROADBLOCKS

Proteomics Has Potential to Address Need for Specific Cancer Biomarkers

Cancer is too often diagnosed and treated too late, when the tumor cells have already invaded and metastasized. At this stage, therapeutic modalities are limited in their success. Detecting cancers at their earliest stages, even in the premalignant state, means that current or future treatment modalities might have a higher likelihood of a true cure. For example, ovarian cancer is usually treated at an advanced stage. The resulting five-year survival rate is 35 percent to 40 percent for patients with late-stage disease who receive the best possible surgical and chemotherapeutic intervention. In contrast, if ovarian cancer is detected at an early stage, conventional therapy produces a high rate of five-year survival (95%) [1]. Thus, early detection, by itself, could have a profound effect on the successful treatment of this disease. A clinically useful biomarker for early cancer detection should be measurable in a readily accessible body fluid, such as serum [2], urine [3], or saliva [4]. Clinical proteomic methods are especially well suited to discovering such biomarkers [5]. Serum or plasma has been the preferred medium for discovery, because this fluid is a protein-rich information reservoir that contains the traces of what has been encountered by the blood during its constant perfusion and percolation throughout the tissues [6].

Type
Chapter
Information
Cancer Metastasis
Biologic Basis and Therapeutics
 , pp. 475 - 485
Publisher: Cambridge University Press
Print publication year: 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Horner, MJ, Ries, LAG, Krapcho, M et al. (eds) (2009) SEER Cancer Statistics Review, 1975–2006. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2006/, based on November 2008 SEER data submission, posted to the SEER website.Google Scholar
Kim, K et al. (2009) Development and validation of a protein-based signature for the detection of ovarian cancer. Clin Lab Med. 29(1): 47–55.CrossRefGoogle ScholarPubMed
Woo, HM et al. (2009) Mass spectrometry based metabolomic approaches in urinary biomarker study of women's cancers. Clin Chim Acta. 400(1–2): 63–9.CrossRefGoogle ScholarPubMed
Arellano-Garcia, ME et al. (2008) Multiplexed immunobead-based assay for detection of oral cancer protein biomarkers in saliva. Oral Dis. 14(8): 705–12.CrossRefGoogle ScholarPubMed
Espina, V, Liotta, , Petricoin, EF 3rd (2009) Reverse-phase protein microarrays for theranostics and patienttailored therapy. Meth Mol Biol. 520: 89–105.CrossRefGoogle Scholar
Hood, BL et al. (2009) Serum proteomics using mass spectrometry. Meth Mol Biol. 520: 107–28.CrossRefGoogle ScholarPubMed
Lopez, MF et al. (2007) A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. Clin Chem. 53(6): 1067–74.CrossRefGoogle ScholarPubMed
Martinkova, J et al. (2009) Challenges in cancer research and multifaceted approaches for cancer biomarker quest. FEBS Lett. 583(11): 1772–84.CrossRefGoogle ScholarPubMed
Petricoin, EF et al. (2006) The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev. 6(12): 961–7.CrossRefGoogle ScholarPubMed
Emery, et al. (2009) Early dysregulation of cell adhesion and extracellular matrix pathways in breast cancer progression. Am J Pathol. 175(3): 1292–302.CrossRefGoogle ScholarPubMed
Ma, XJ et al. (2009) Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res. 11(1): R7.CrossRefGoogle ScholarPubMed
Vaillant, F et al. (2008) The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res. 68(19): 7711–7.CrossRefGoogle ScholarPubMed
Zhou, M, Veenstra, T (2008) Mass spectrometry: m/z 1983–2008. BioTechniques. 44(5): 667–8, 670.CrossRefGoogle ScholarPubMed
Kiehntopf, M, Siegmund, R, Deufel, T (2007) Use of SELDI-TOF mass spectrometry for identification of new biomarkers: potential and limitations. Clin Chem Lab Med. 45(11): 1435–49.CrossRefGoogle ScholarPubMed
Kulasingam, V, Diamandis, EP (2008) Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Prac. 5(10): 588–99.Google ScholarPubMed
Brown, PO, Palmer, C (2009) The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med. 6(7): e1000114.CrossRefGoogle ScholarPubMed
Fredolini, C et al. (2008) Concentration and preservation of very low abundance biomarkers in urine, such as human growth hormone (hGH), by Cibacron blue F3G-A loaded hydrogel particles. Nano Res. 1: 502–518.CrossRefGoogle Scholar
Longo, C et al. (2009) Core-shell hydrogel particles harvest, concentrate and preserve labile low abundance biomarkers. PloS One. 4(3): e4763.CrossRefGoogle ScholarPubMed
Luchini, A et al. (2008) Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation. Nano Lett. 8(1): 350–61.CrossRefGoogle ScholarPubMed
Luchini, A et al. (2009) Nanoparticle technology: Addressing the fundamental roadblocks to protein biomarker discovery. J Mat Chem. 19: 5071–7.CrossRefGoogle ScholarPubMed
Geho, DH et al. (2006) Nanoparticles: potential biomarker harvesters. Curr Opin Chem Biol. 10(1): 56–61.CrossRefGoogle ScholarPubMed
Liotta, , Ferrari, M, Petricoin, E (2003) Clinical proteomics: written in blood. Nature. 425(6961): 905.CrossRefGoogle ScholarPubMed
O'Connell, CD, Atha, DH, Jakupciak, JP (2005) Standards for validation of cancer biomarkers. Cancer Biomarkers. 1(4–5): 233–9.CrossRefGoogle ScholarPubMed
Mandrekar, SJ, Sargent, DJ (2009) Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol. 27(24):. 4027–34.CrossRefGoogle ScholarPubMed
Metzger, J et al. (2009) Adapting mass spectrometry-based platforms for clinical proteomics applications: the capillary electrophoresis coupled mass spectrometry paradigm. Crit Rev Clin Lab Sci. 46(3): 129–52.CrossRefGoogle ScholarPubMed
Govorukhina, NI et al. (2009) Influence of clotting time on the protein composition of serum samples based on LC-MS data. J Chromatogr 877(13): 1281–91.Google ScholarPubMed
Ye, B et al. (2003) Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res. 9(8): 2904–11.Google ScholarPubMed
Yang, X, Lazar, IM (2009) MRM screening/biomarker discovery with linear ion trap MS: a library of human cancer-specific peptides. BMC Cancer. 9: 96.CrossRefGoogle ScholarPubMed
Whiteley, GR et al. (2009) Analytical considerations for mass spectrometry profiling in serum biomarker discovery. Clin Lab Med. 29(1): 57–69.CrossRefGoogle ScholarPubMed
Espina, V et al. (2006) Laser-capture microdissection. Nature Protocols. 1(2): 586–603.CrossRefGoogle ScholarPubMed
Bonner, RF et al. (1997) Laser capture microdissection: molecular analysis of tissue. Science. 278(5342): 1481–3.CrossRefGoogle Scholar
Emmert-Buck, MR et al. (1996) Laser capture microdissection. Science. 274(5289): 998–1001.CrossRefGoogle ScholarPubMed
Emmert-Buck, MR et al. (1997) Localization of the multiple endocrine neoplasia type I (MEN1) gene based on tumor loss of heterozygosity analysis. Cancer Res. 57(10): 1855–8.Google ScholarPubMed
Westbury, CB et al. (2009) Genome-wide transcriptomic profiling of microdissected human breast tissue reveals differential expression of KIT (c-Kit, CD117) and oestrogen receptor-alpha (ERalpha) in response to therapeutic radiation. J Pathol. 219(1): 131–40.CrossRefGoogle ScholarPubMed
Domazet, B et al. (2008) Laser capture microdissection in the genomic and proteomic era: targeting the genetic basis of cancer. Int J Clin Exper Pathol. 1(6): 475–88.Google Scholar
Ma, XJ et al. (2003) Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA. 100(10): 5974–9.CrossRefGoogle ScholarPubMed
Pierobon, M et al. (2009) Multiplexed cell signaling analysis of metastatic and nonmetastatic colorectal cancer reveals COX2-EGFR signaling activation as a potential prognostic pathway biomarker. Clin Colorectal Cancer. 8(2): 110–7.CrossRefGoogle ScholarPubMed
Wulfkuhle, JD et al. (2008) Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res. 7(4): 1508–17.CrossRefGoogle ScholarPubMed
Preisinger, C et al. (2008) Proteomics and phosphoproteomics for the mapping of cellular signalling networks. Proteomics. 8(21): 4402–15.CrossRefGoogle ScholarPubMed
Overdevest, JB, Theodorescu, D, Lee, JK (2009) Utilizing the molecular gateway: the path to personalized cancer management. Clin Chem. 55(4): 684–97.CrossRefGoogle ScholarPubMed
Cross, D, Burmester, JK (2004) The promise of molecular profiling for cancer identification and treatment. Clin Med Res. 2(3): 147–50.CrossRefGoogle ScholarPubMed
Marchionni, L et al. (2008) Systematic review: gene expression profiling assays in early-stage breast cancer. Ann Intern Med. 148(5): 358–69.CrossRefGoogle ScholarPubMed
Noble, ME, Endicott, JA, Johnson, LN (2004) Protein kinase inhibitors: insights into drug design from structure. Science. 303(5665): 1800–5.CrossRefGoogle ScholarPubMed
Manning, G et al. (2002) The protein kinase complement of the human genome. Science. 298(5600): 1912–34.CrossRefGoogle ScholarPubMed
Paweletz, CP et al. (2001) Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene. 20(16): 1981–9.CrossRefGoogle ScholarPubMed
VanMeter, A et al. (2007) Reverse-phase protein microarrays: application to biomarker discovery and translational medicine. Expert Rev Mol Diagn. 7(5): 625–33.CrossRefGoogle ScholarPubMed
Speer, R et al. (2008) Molecular network analysis using reverse phase protein microarrays for patient-tailored therapy. Adv Exp Med Biol. 610: 177–86.CrossRefGoogle ScholarPubMed
Zong, Y et al. (2007) Forward-phase and reverse-phase protein microarray. Methods Mol Biol. 381: 363–74.Google ScholarPubMed
Soule, BP et al. (2007) Reverse phase protein microarray reveals a correlation between Akt activation and altered insulin-like growth factor receptor expression following exposure to ionizing radiation. Int J Radiat Oncol Biol Physics. 69(3): S622.CrossRefGoogle Scholar
Espina, V, Wulfkuhle JD, Liotta (2009) Application of laser microdissection and reverse-phase protein microarrays to the molecular profiling of cancer signal pathway networks in the tissue microenvironment. Clin Lab Med. 29(1): 1–13.CrossRefGoogle ScholarPubMed
Espina, V et al. (2008) A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics. 7(10): 1998–2018.CrossRefGoogle ScholarPubMed
Hood, BL et al. (2005) Proteomic analysis of formalin-fixed prostate cancer tissue. Mol Cell Proteomics. 4(11): 1741–53.CrossRefGoogle ScholarPubMed
Hait, WN, Hambley, TW (2009) Targeted cancer therapeutics. Cancer Res. 69(4): 1263–7; discussion 1267.CrossRefGoogle ScholarPubMed
Joyce, JA, Pollard, JW (2009) Microenvironmental regulation of metastasis. Nat Rev. 9(4): 239–52.CrossRefGoogle Scholar
Mbeunkui, F, Johann, DJ Jr (2009) Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol. 63(4): 571–82.CrossRefGoogle ScholarPubMed
Chandrasekharappa, SC et al. (1997) Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 276(5311): 404–7.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×